Finding a Cure for Cancer Is Vehemently Coming Closer Thanks to Eric Lefkofsky

Eric Lefkofsky is a 49 years old gentleman who has launched at least five companies, each worth a minimum of $250 million. Tempus is one of his most significant investments as it uses data to solve cancer-related issues.

After Eric Lefkofsky’s wife was diagnosed with breast cancer, he realized that very little data was used to contribute to her care. This ultimately launched Tempus, whose goal is to analyze information and thus help doctors customize treatment for each cancer patient.

How Does Tempus Work?

A doctor collects a tumor sample and sends it to Tempus for genomic sequencing. Consequently, Tempus identifies the reason behind cell growth and division. This analysis helps doctors to prescribe better treatment other than chemotherapy.

Although genomic sequencing costs between $1000 and $5000, Tempus loses money while doing it. Why? Probably because they do extensive analysis contrary to what other organizations do. Nonetheless, the company has licensed its library to insurers, researchers, and drug companies, and it increases their revenue. In fact, it collects seven figures from seven out of ten leading drug companies.

Several people have invested in Tempus with the hope of achieving better results on cancer, depression, and diabetes. It has, however, published less than 20 peers reviewed manuscript in four years while its competitor has published 400 in nine years.

Entrepreneur Journey of Eric

Eric Lefkofsky’s journey started at the University of Michigan. He studied history but ventured into entrepreneurship as he began by selling carpets. He later co-founded InnerWorkings, which was a marketing company. He then started a transportation company, Echo Global Logistics, and MediaOcean, an advertising software.

Groupon is another company that he invested in, and it’s known as one of his most significant achievements, as illustrated by the $1.6 billion in revenue collected in 2016. Eric Lefkofsky has done other projects from different industries, and all the experience has led to the creation of Tempus. He hopes to produce more data following the genomic sequence his company is predicted to carry.

Tempus has made a significant milestone as it is currently working with 30% oncologists from the USA. Find out more about Eric Lefkofsky: https://newsblaze.com/business/latest-business/eric-lefkofsky-about-tempus-at-bloombergs-the-year-ahead-summit_146430/

Comments are Disabled